SEVERITY OF ABDOMINAL OBESITY AND CARBOHYDRATE METABOLISM DISORDERS IN MENOPAUSAL WOMEN AND POTENTIALS FOR THE CORRECTION OF THE REVEALED VIOLATIONS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

To date, the frequency of the use of menopausal hormone therapy (MHT) for the correction of climacteric syndrome and metabolic disorders is still low due to possible complications of such therapy. Not only the low dose of estrogen, but characteristics of progestogen in the composition of combined mode of MHT have a great significance. The results of evaluation of changes in abdominal obesity (AO), and carbohydrate metabolism disorders in women in early postmenopause against the background of long-term combined MHT with 1 mg E2/2 mg drospirenone (DRSP) are presented. This study demonstrates the possibility of use of combination of 1 mg E2/2 mg DRSP for long-term MHT in women in early postmenopause with metabolic disorders.

全文:

受限制的访问

作者简介

S. Tolstov

FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky “; SHCI “Saratov City Clinical Hospital № 1 n.a. Yu.Ya. Gordeyev"

Saratov

I. Salov

FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky “; SHCI “Saratov City Clinical Hospital № 1 n.a. Yu.Ya. Gordeyev"

Saratov

A. Rebrov

FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky “

Email: andreyrebrov@yandex.ru
MD, Prof., Head of the Department of Hospital Therapy of the Medical Faculty Saratov

参考

  1. Юренева С.В., Ильина Л.М. Старение репродуктивной системы женщин: от теории к клинической практике. Часть II. Роль гормо нальной терапии в решении проблем переходного периода и ранней постменопаузы. Акушерство и гинекология. 2014;4:17-24.
  2. de Villiers T.J., Pines A., Panay N. Gambacciani M., Archer D.F., Baber R.J. Davis S.R., Gompel A.A., Henderson V.W. Langer R., Lobo R.A., Plu-Bureau G., Sturdee D.W.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16:316-37.
  3. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации (протокол лечения). Письмо Минздрава России от 02.10.2015 №15-4/10/2-5804.
  4. Baber R.J., Panay N., Fenton A., IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50.
  5. Elger W., Beier S., Pollow K., Garfield R., Shi S.Q., Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003; 68:891-905.
  6. Archer D. Efficacy and safety of drospirenoneestradiol for hormone therapy: a double blind, randomized multicenter trial. Menopause. 2005;12(6):716-27.
  7. Gambacciani M., Rosano G., Cappagli B., Pepe A., Vitale C., Genazzani A.R. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric. 2011;14:18-24.
  8. Григорян О.Р., Андреева Е.Н. Использование препарата «Анжели» у женщин с сахарным диабетом 2 типа и артериальной гипертензией в период постменопаузы. РМЖ. 2007;3:197-201.
  9. Rizzo M.R., Leo S., De Franciscis P., Colacurci N., Paolisso G. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/ dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age. 2014;36(1):265-74.
  10. Villa P., Suriano R., Ricciardi L., Tagliaferri V., De Cicco S., De Franciscis P., Colacurci N., Lanzone A. Low-doseestrogen and drospirenone combination: effects on glycoinsulinemicmetabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil. Steril. 2011;95:158-63.
  11. Репина М.А., Зинина Т.А., Кузьмина-Крутецкая С.Р. Заместительная гормональная терапия препаратом «Анжелик» состояние углеводного обмена и гемостаз. Журн. акушерства и женских болезней. 2006;1:70-5.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##